Self-emulsifying composition containing sulfonamide derivative and self-emulsifying drug delivery system
By preparing a self-emulsifying composition containing sulfonamide derivatives and solubilizers, the problems of low solubility and membrane permeability of large molecular weight compounds during oral administration are solved, achieving efficient absorption and dissolution of the compounds in the gastrointestinal tract, making them suitable for the treatment of a variety of inflammatory diseases.
Patent Information
- Application Number
- CN202480023692.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-04-06
- Filing Date
- 2024-04-05
- Publication Date
- 2025-11-04
AI Technical Summary
Compounds with a molecular weight of 500 or greater have problems with low solubility and membrane permeability when administered orally. Existing self-emulsifying drug delivery systems (SEDDS) have failed to effectively improve their absorption, and it is unclear which components can be combined with the compound to improve solubility and membrane permeability.
The solubility and permeability in the gastrointestinal tract are optimized by preparing a self-emulsifying composition comprising a sulfonamide derivative represented by formula (1), a pharmaceutically acceptable salt thereof or an active metabolite thereof, and at least two solubilizers, including a surfactant and an auxiliary surfactant.
It significantly improves the blood exposure and absorption of the compound, enhances its solubility and membrane permeability in the gastrointestinal tract, and is suitable for the treatment or prevention of inflammatory diseases.
Smart Images

Figure CN120897744A_ABST
Abstract
Description
Technical Field
[0001] This disclosure relates to a self-emulsifying composition containing a sulfonamide derivative and a self-emulsifying drug delivery system. Background Technology
[0002] Compounds with a molecular weight of 500 or greater are known to have low water solubility and low membrane permeability when orally administered (Donovan, MD et al. (1990) Absorption of polyethylene glycols 600 through 2000: The molecular weight dependence of gastrointestinal and nasal absorption. Pharm. Res. 7, 863-868). In the preparation of pharmaceutical products containing such compounds, reduced absorption is a problem due to low solubility or membrane permeability in the gastrointestinal tract after oral administration. Therefore, various pharmaceutical measures have been taken to improve the absorption of compounds. For example, self-emulsifying drug delivery systems (hereinafter referred to as "SEDDS") composed of oils, surfactants, etc., are one such measure. SEDDS are formulations prepared by uniformly mixing, dissolving, or dispersing the active ingredient in an anhydrous state. In the case of oral administration of SEDDS, the SEDDS disperses or dissolves in the aqueous contents of the gastrointestinal tract to form an emulsion, thus expecting improved solubility and membrane permeability of the contained compound and improved absorption.
[0003] According to published information, as a study on improving membrane permeability or absorbability, Japanese Patent Application Publication No. 2021-169476 investigated the possibility of applying SEDDS to medium molecular weight compounds with low membrane permeability, the Japanese translation of the publication of PCT International Application No. 2022-540780 investigated tetrahydropyrazolopyrimidinone compounds, and Japanese Patent Application Publication No. 2021-107433 investigated ω3 polyunsaturated fatty acids.
[0004] It has been reported that sulfonamide derivatives represented by the following formula (1), their pharmaceutically acceptable salts, or their active metabolites have α4 integrin inhibitory activity and can be used as agents for the treatment or prevention of inflammatory bowel disease, etc. (International Publication No. WO2017 / 135472). However, findings regarding the membrane permeability or absorption of such compounds with a molecular weight of 500 or greater are not satisfactory.
[0005] Summary of the Invention
[0006] The problem this invention aims to solve Even compounds with molecular weights of 500 or greater possess a variety of physical properties, such as solubility and membrane permeability, and it is unclear whether the use of SEDDS can improve the absorption of compounds. Furthermore, it is unknown what components can be combined with compounds to prepare SEDDS that improve solubility and membrane permeability.
[0007] Regarding the sulfonamide derivatives represented by formula (1) above, their pharmaceutically acceptable salts, or their active metabolites, the inventors' research reveals that there is room for improvement in blood exposure when the compound is administered orally as a powder or suspension. In other words, further improvements in membrane permeability and absorbability are desired.
[0008] This disclosure was made by the inventors through careful study in view of the circumstances, and one of the objects of this disclosure is to provide a pharmaceutical composition comprising a sulfonamide derivative represented by formula (1), a pharmaceutically acceptable salt thereof or an active metabolite thereof, and having enhanced absorption when administered orally.
[0009] In order to solve the above problems, the inventors conducted various studies and found that the absorbability of sulfonamide derivatives represented by formula (1), their pharmaceutically acceptable salts or their active metabolites can be improved by preparing self-emulsifying compositions, thereby completing the present invention, the self-emulsifying compositions comprising: sulfonamide derivatives represented by formula (1), their pharmaceutically acceptable salts or their active metabolites; and at least two solubilizers.
[0010] The non-limiting aspects of this disclosure provide the following technical ideas.
[0011] [1] A self-emulsifying composition comprising: a sulfonamide derivative represented by formula (1), a pharmaceutically acceptable salt thereof, or an active metabolite thereof; and at least two solubilizers. . [2] According to the self-emulsifying composition of [1], wherein the at least two solubilizers comprise at least one surfactant and at least one auxiliary surfactant.
[0012] [3] The self-emulsifying composition according to [1], wherein the solubilizer comprises at least two selected from cyclodextrin or derivatives thereof, bile acids or derivatives thereof, fatty alcohols, fatty acids or derivatives thereof, and tocopherol derivatives.
[0013] [4] The self-emulsifying composition according to [2], wherein the surfactant comprises at least one selected from the group consisting of polyglycerol-2 dioleate, polyglycerol-3 dioleate, polyglycerol-10 trioleate, propylene glycol monolaurate, propylene glycol monocaprylate, glyceryl monocaprylate, glyceryl monolaurate, glyceryl dilaurate, and glyceryl monolinoleate.
[0014] [5] The self-emulsifying composition according to [2], wherein the auxiliary surfactant comprises selected from polyoxyethylene 40 castor oil, polyoxyethylene 35 castor oil, PEG-25 trioleate, PEG-60 corn glyceride, PEG-60 almond oil, PEG-40 palm kernel oil, PEG-50 castor oil, PEG-50 hydrogenated castor oil, PEG-60 hydrogenated castor oil, PEG-8 caprylic / capric glyceride, lauroyl polyoxyethylene-32 glyceride, linoleyl polyoxyethylene- At least one of the group consisting of 6-glyceryl ester, oleoyl polyoxyethylene-6-glyceryl ester, stearoyl polyoxyethylene-32-glyceryl ester, PEG-6 caprylic / capric glyceryl ester, polyglycerol-10 monooleate, polyglycerol-10 laurate, polyglycerol-15 hydroxystearate, α-tocopherol PEG-400 succinate, α-tocopherol PEG-1000 succinate, dl-α-tocopherol PEG-1000 succinate, and d-α-tocopherol PEG-1000 succinate.
[0015] [6] The self-emulsifying composition according to any one of [2], [4] and [5], wherein The content of the surfactant is 0.1 times or more by mass% relative to the sulfonamide derivative or its pharmaceutically acceptable salt represented by formula (1), and The content of the auxiliary surfactant is 10 times or less relative to the sulfonamide derivative or its pharmaceutically acceptable salt represented by formula (1).
[0016] [7] The self-emulsifying composition according to any one of [2] and [4] to [6], wherein the ratio of the surfactant to the auxiliary surfactant is 1:1 to 8:1.
[0017] [8] The self-emulsifying composition according to any one of [2] and [4] to [7], wherein the surfactant comprises propylene glycol monooctanoate.
[0018] [9] The self-emulsifying composition according to any one of [2] and [4] to [8], wherein the auxiliary surfactant comprises polyoxyethylene 40 castor oil, polyoxyethylene 35 castor oil or polyoxyethylene castor oil.
[0019]
[10] The self-emulsifying composition according to any one of [1] to [9] further comprises a co-solvent.
[0020]
[11] A self-emulsifying drug delivery system in the form of a formulation suitable for oral administration, comprising a self-emulsifying composition according to any one of [1] to
[10] .
[0021]
[12] According to the self-emulsifying drug delivery system of
[11] , wherein the formulation is a capsule.
[0022] In addition, the following technical ideas are provided as different aspects of this disclosure.
[0023] [2-1] A therapeutic or preventive agent for a disease comprising a self-emulsifying composition comprising: a sulfonamide derivative represented by formula (1), a pharmaceutically acceptable salt thereof or an active metabolite thereof; and at least two solubilizers.
[0024] [2-2] The therapeutic or preventive agent according to [2-1], wherein the disease is an inflammatory disease in which the pathology involves an α4 integrin-dependent adhesion process.
[0025] [2-3] The therapeutic or preventive agent according to [2-1] or [2-2], wherein the disease is rheumatoid arthritis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus, multiple sclerosis, Sjogren's syndrome, asthma, psoriasis, allergy, diabetes, cardiovascular disease, arteriosclerosis, restenosis, tumor growth, tumor metastasis, transplant rejection and / or human immunodeficiency virus infection.
[0026] [2-4] The therapeutic or preventive agent according to [2-3], wherein the disease is ulcerative colitis or Crohn's disease.
[0027] [2-5] A method of treating or preventing disease using a self-emulsifying composition comprising: a compound represented by formula (1), a pharmaceutically acceptable salt thereof or an active metabolite thereof; and at least two solubilizers.
[0028] [2-6] According to the method described in [2-5], the disease is an inflammatory disease in which the pathology involves α4 integrin-dependent adhesion processes.
[0029] [2-7] The disease is rheumatoid arthritis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus, multiple sclerosis, Sjögren's syndrome, asthma, psoriasis, allergy, diabetes, cardiovascular disease, arteriosclerosis, restenosis, tumor growth, tumor metastasis, transplant rejection and / or human immunodeficiency virus infection, according to the method described in [2-5] or [2-6].
[0030] [2-8] The method described in [2-7] is ulcerative colitis or Crohn's disease.
[0031] [2-9] Use of the self-emulsifying composition according to any one of [1] to
[10] for producing a therapeutic or preventive agent for inflammatory diseases involving α4 integrin-dependent adhesion processes in pathology.
[0032] [2-10] According to the uses described in [2-9], the diseases described are rheumatoid arthritis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus, multiple sclerosis, Sjögren's syndrome, asthma, psoriasis, allergy, diabetes, cardiovascular disease, arteriosclerosis, restenosis, tumor growth, tumor metastasis, transplant rejection and / or human immunodeficiency virus infection.
[0033] [2-11] According to the use described in [2-10], the disease described is ulcerative colitis or Crohn's disease.
[0034] [2-12] According to the self-emulsifying composition of [3], wherein the fatty acid or its derivative is an amide ester of fatty acid, an ester of fatty acid and hydroxy acid, a sugar ester or sugar ester derivative of fatty acid, an ester of fatty acid with propylene glycol, an ester of fatty acid with glycerol, an ester of fatty acid with polyglycerol, an ester of fatty acid with ethylene glycol, an ester of fatty acid with polyethylene glycol, or an ester of fatty acid with macrogol glycerin.
[0035] In addition, the following technical ideas are provided as different aspects of this disclosure.
[0036] [3-1] A self-emulsifying composition comprising: a sulfonamide derivative represented by formula (1), a pharmaceutically acceptable salt thereof or an active metabolite thereof; and at least two solubilizers, wherein the total amount of said solubilizers is 10% or more and 90% or less by mass relative to the total mass of said self-emulsifying composition.
[0037] [3-2] According to the self-emulsifying composition of [3-1], the total content of said solubilizer is 20% or more and 90% or less by mass relative to the total mass of said self-emulsifying composition.
[0038] [3-3] According to the self-emulsifying composition of [3-1], the total content of said solubilizer is 30% or more and 90% or less by mass relative to the total mass of said self-emulsifying composition.
[0039] [3-4] According to the self-emulsifying composition of [3-1], the total content of the solubilizer is 40% or more and 90% or less by mass relative to the total mass of the self-emulsifying composition.
[0040] [3-5] The self-emulsifying composition according to any one of [3-1] to [3-4], wherein the solubilizer comprises at least one surfactant, and the content of the surfactant is 5% by mass or more and 85% by mass or less relative to the total mass of the self-emulsifying composition.
[0041] [3-6] The self-emulsifying composition according to any one of [3-1] to [3-4], wherein the solubilizer comprises at least one surfactant, and the content of the surfactant is 10% by mass or more and 80% by mass or less relative to the total mass of the self-emulsifying composition.
[0042] [3-7] The self-emulsifying composition according to any one of [3-1] to [3-5], wherein the solubilizer comprises at least one auxiliary surfactant, and the content of the auxiliary surfactant is 5% by mass or more and 85% by mass or less relative to the total mass of the self-emulsifying composition.
[0043] [3-8] A self-emulsifying composition according to any one of [3-1] to [3-4] and [3-6], wherein the solubilizer comprises at least one auxiliary surfactant, and the content of the auxiliary surfactant is 10% by mass or more and 80% by mass or less relative to the total mass of the self-emulsifying composition.
[0044] [3-9] According to the self-emulsifying composition of
[10] , wherein the co-solvent is a co-solvent selected from the group consisting of acetic acid, sorbitol, mannitol, glycerol, triacetin, triethyl citrate, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, propylene carbonate, ethanol and propylene glycol.
[0045] [3-10] The self-emulsifying composition according to [3-9], wherein the co-solvent is ethanol or propylene glycol.
[0046] [3-11] The self-emulsifying composition according to any one of
[10] , [3-9] and [3-10], wherein the content of the co-solvent is 10% by mass or less relative to the total mass of the self-emulsifying composition.
[0047] [3-12] According to the self-emulsifying composition of [3-11], the content of the co-solvent is 8% by mass or less relative to the total mass of the self-emulsifying composition.
[0048] [3-13] According to the self-emulsifying composition of [3-12], the content of the co-solvent is 5% by mass or less relative to the total mass of the self-emulsifying composition.
[0049] [3-14] The self-emulsifying composition according to any one of [1] to
[10] further comprises an additive.
[0050] [3-15] The self-emulsifying composition according to [3-14], wherein the additive is at least one selected from the group consisting of excipients, lubricants, binders, pH adjusters, flavoring agents, thickeners, buffers, colorants, diluents, preservatives and sweeteners.
[0051] [3-16] According to the self-emulsifying composition of [2] or [4], the mass ratio of the sulfonamide derivative represented by formula (1) or a pharmaceutically acceptable salt thereof to the surfactant is 1:1 to 1:8.
[0052] [3-17] According to the self-emulsifying composition of [2] or [5], the mass ratio of the sulfonamide derivative represented by formula (1) or a pharmaceutically acceptable salt thereof to the auxiliary surfactant is 1:1 to 1:8.
[0053] [3-18] A self-emulsifying composition comprising 10 to 1000 mg of a sulfonamide derivative represented by formula (1), a pharmaceutically acceptable salt thereof, or an active metabolite thereof.
[0054] By providing a self-emulsifying composition comprising at least two solubilizers in addition to a sulfonamide derivative represented by formula (1), its pharmaceutically acceptable salt or its active metabolite, this disclosure is able to improve the absorption of the compound, its pharmaceutically acceptable salt or its active metabolite. Attached Figure Description
[0055] Figure 1 This shows the logarithm of the AUC for the test tube method (Test tube Method Log(AUC)). 0-2.25 A graph showing the correlation between the AUC of rat PO / PK and the logarithm of plasma concentration (rat PO / PK Log(AUC)).
[0056] Figure 2 This shows the logarithm of the AUC for the test tube method (Test tube Method Log(AUC)). 0-2.25 A graph showing the correlation between the elution rate (%) and the dissolution rate (%) at pH 2.4.
[0057] Figure 3 This shows the logarithm of the AUC for the test tube method (Test tube Method Log(AUC)). 0-2.25 A graph showing the correlation between the elution rate (%) and the dissolution rate (%) at pH 6.4. Detailed Implementation
[0058] This disclosure will be described in detail below. It should be noted that the embodiments described below are one aspect of this disclosure and are not intended to limit the scope of this disclosure.
[0059] In this disclosure, the sulfonamide derivative represented by the following formula (1) (sometimes referred to as "compound (1)" in this specification) is a compound having α4 integrin inhibitory activity and is also called 2-methylpropyl(2S)-2-{2,5-difluoro-4-[4-(2,2-dimethylpropylamide)phenylsulfonamide]benzamide}-3-{2-[1,6-dimethyl-2,4-dioxo-1,4-dihydropyrimidin-3(2H)-yl]pyridin-5-yl}propionic acid. Regardless of the name, the scope of this disclosure will be recognized by those skilled in the art by referring to the above-mentioned compound. The compound can be obtained by known methods, which are not limited thereto but include, for example, the methods described in International Publication No. WO2017 / 135472, as synthetic methods.
[0060] In this disclosure, a "pharmaceutically acceptable salt" simply means a pharmaceutically acceptable salt in which the sulfonamide derivative represented by formula (1) above can be in salt form while retaining its pharmacological activity. For acidic groups such as the carboxyl group in the formula, this includes, for example, ammonium salts; alkali metal salts such as sodium and potassium; alkaline earth metal salts such as calcium and magnesium; aluminum salts; zinc salts; salts with organic amines such as triethylamine, ethanolamine, morpholine, piperidine, or dicyclohexylamine; and salts with basic amino acids such as arginine or lysine. Furthermore, for basic groups in the formula, pharmaceutically acceptable salts include salts with inorganic acids such as hydrochloric acid, sulfuric acid, or phosphoric acid; salts with organic carboxylic acids such as acetic acid, citric acid, benzoic acid, maleic acid, fumaric acid, tartaric acid, or succinic acid; and salts with organic sulfonic acids such as methanesulfonic acid or p-toluenesulfonic acid. In addition, as a method for forming salt, a known method may be used appropriately, and the method includes, for example, mixing the sulfonamide derivative represented by formula (1) with the desired acid or base in a suitable ratio in a solvent or dispersion medium, or the salt may be obtained by conversion from another form of salt by a method such as ion exchange.
[0061] In this disclosure, "active metabolite" refers to a group of compounds that have α4 integrin inhibitory activity and are obtained by conversion of sulfonamide derivatives represented by formula (1) in vivo under physiological conditions via enzymes, gastrointestinal fluids, etc. Conversion reactions include reduction reactions such as oxidation, reduction, and hydrolysis. Non-limiting examples of active metabolites include compounds represented by formula (2) (sometimes referred to as "compound (2)" in this specification).
[0062] "Self-emulsifying composition" refers to a composition having the property of emulsifying in an aqueous medium to form an emulsion (self-emulsifying property), and includes self-nanoemulsifying compositions and self-microemulsifying compositions. The emulsion to be formed can have any size, therefore all self-emulsifying drug delivery systems (SEDDS), self-microemulsifying drug delivery systems (SMEDDS), and self-nanoemulsifying drug delivery systems (SNEDDS) that are generally distinguished by the diameter of the emulsion are within the scope of the self-emulsifying compositions of this disclosure.
[0063] The self-emulsifying compositions of this disclosure can be prepared by known methods. Furthermore, the properties of the self-emulsifying compositions thus prepared can be appropriately evaluated by known methods. In a non-limiting aspect of evaluating the properties of the self-emulsifying compositions, particle size is known as an indicator of the physical properties of the emulsion. Conventionally known methods can be used as methods for evaluating particle size. For example, dynamic light scattering (DLS) can be used. Additionally, as a parameter reflecting particle size, methods for evaluating turbidity using a turbidimeter can also be used.
[0064] In the self-emulsifying composition of this disclosure, the content of the sulfonamide derivative represented by formula (1), its pharmaceutically acceptable salt, or its active metabolite is not particularly limited, but is preferably 10 mg or more, more preferably 50 mg or more, and even more preferably 100 mg or more, and preferably 1000 mg or less, more preferably 800 mg or more, and even more preferably 400 mg or less. Furthermore, in the self-emulsifying composition of this disclosure, the sulfonamide derivative represented by formula (1), its pharmaceutically acceptable salt, or its active metabolite is preferably included in an amount of 10 to 1000 mg, more preferably in an amount of 50 to 800 mg, and even more preferably in an amount of 100 to 400 mg. When the total mass of the self-emulsifying composition of this disclosure is considered as 100%, the content of the sulfonamide derivative represented by formula (1), its pharmaceutically acceptable salt, or its active metabolite is preferably 1% by mass or more, more preferably 5% by mass or more, and preferably 50% by mass or less, and even more preferably 30% by mass or less.
[0065] The self-emulsifying composition disclosed herein contains at least two solubilizers. "Solubilizer" means a suitable medium that can enhance the solubility of the target solute. Within the scope of this disclosure, solubilizers are not particularly limited as long as they are known as solubilizers, but preferably include solubilizers belonging to any of the following: cyclodextrins (e.g., β-cyclodextrin or γ-cyclodextrin), cyclodextrin derivatives (e.g., sulfobutyl ether or hydroxypropyl ether), bile acids, bile acid derivatives (e.g., cholates, ursodeoxycholates, chenodeoxycholates, taurose-chenodeoxycholates, taurose-ursodeoxycholates, glycocyanochenodeoxycholates or glycocyanoursodeoxycholates), fatty acids (e.g., capric acid, caprylic acid, lauric acid, sarcosine, palmitic acid, myristic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, ricinoleic acid, arachidonic acid, behenic acid and pharmaceutically acceptable salts of these acids), fatty acid derivatives, alcohols, fatty alcohols (e.g., stearyl alcohol), fatty alcohol derivatives (e.g., polyethylene glycol octadecyl ether), and tocopherol derivatives. Preferred fatty acid derivatives include sodium dioctyl sulfosuccinate, sodium lauryl sulfate, amide esters of fatty acids (e.g., diethanolamide lauryl sarcosinate, sodium lauroyl sarcosinate, lauroyl carnitine, palmitoyl carnitine, or myristoyl carnitine), esters of fatty acids or fatty alcohols with hydroxy acids (e.g., sodium stearoyl lactylate or sodium lauryl lactylate), glycol esters of fatty acids, and glycol ester derivatives (e.g., glucono monooctyl ester, diglucono monooctyl ester, sucrose laurate, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monooleate, sorbitan monostearate, sorbitan tristearate, sucrose myristate, or poly(hydroxylamine) esters. Ethylene oxide (20) dehydrated sorbitan oleate (polysorbate 80), fatty acid esters of lower alcohols, fatty acid esters with propylene glycol, fatty acid esters with glycerol, fatty acid esters with polyglycerol, fatty acid esters with ethylene glycol, fatty acid esters with polyethylene glycol, fatty acid esters with polyethylene glycol (also known as polyoxyglycerol), triglycerides (e.g., corn oil, almond oil, coconut oil, castor oil, hydrogenated castor oil or hydrogenated coconut oil), fatty acid esters with propylene glycol and mixtures of fatty acid esters with polyethylene glycol, and polyglycerized fatty acids.
[0066] As the total content of the solubilizer, the solubilizer can be blended in a desired ratio, as long as an emulsion is formed and exhibits self-emulsifying properties. For example, when the total mass of the self-emulsifying composition is considered as 100%, the total content of the solubilizer can be 10% by mass or more, 20% by mass or more, 30% by mass or more, 40% by mass or more, or 50% by mass or more. For example, when the total mass of the self-emulsifying composition is considered as 100%, the total content of the solubilizer can be 90% by mass or less. Although not limited thereto, when the total mass of the self-emulsifying composition is considered as 100%, the total content of the solubilizer can be 10% by mass or more and 90% by mass or less. The total content of the solubilizer is preferably 20% by mass or more and 90% by mass or less, more preferably 30% by mass or more and 90% by mass or less, further preferably 40% by mass or more and 90% by mass or less, even more preferably 50% by mass or more and 90% by mass or less, and particularly preferably 60% by mass or more and 90% by mass or less.
[0067] Furthermore, in one aspect of this disclosure, the solubilizer contains at least one surfactant and at least one auxiliary surfactant.
[0068] "Surfactant" refers to the group of solubilizers described above that exhibit lipophilicity. However, it is not limited to this; the hydrophilic-lipophilic balance (HLB) can be used as an indicator of lipophilicity. HLB is obtained by dividing the substance without hydrophilic groups into equal portions with HLB=0 and the substance without lipophilic groups into equal portions with HLB=20, and can be calculated, for example, by methods known to those skilled in the art, such as the Griffin method. In this disclosure, HLB refers to the value calculated by the Griffin method. Generally, the smaller the HLB, the higher the lipophilicity. Therefore, in the self-emulsifying compositions of this disclosure, solubilizers having relatively small HLBs can be suitably selected as surfactants. For example, in this disclosure, solubilizers with an HLB of 7 or lower can be selected as "surfactants". Specifically, the surfactant is an ester of fatty acid with propylene glycol, an ester of fatty acid with glycerol, or an ester of fatty acid with polyglycerol (HLB ≤ 7), and more specifically, polyglycerol-2 dioleate, polyglycerol-3 dioleate, polyglycerol-10 trioleate, propylene glycol monolaurate, propylene glycol monocaprylate, glyceryl monocaprylate, glyceryl monolaurate, glyceryl dilaurate, glyceryl monolinoleate, etc. These surfactants may be suitably synthesized by known methods or may be commercially available. Non-limiting examples of commercial products include those with names such as Caprol, Capryol, Capmul, Lauroglycol, and Plurol Oleique in part of their product names. One of these surfactants may be used alone, or two or more of these surfactants may be combined.
[0069] When the total mass of the self-emulsifying composition of this disclosure is considered as 100%, the content of surfactant is preferably 5% by mass or more, more preferably 10% by mass or more, and preferably 85% by mass or less, and more preferably 80% by mass or less. Furthermore, when the content of the sulfonamide derivative represented by formula (1), its pharmaceutically acceptable salt, or its active metabolite is considered as 1 with respect to the sulfonamide derivative represented by formula (1), the content of surfactant is 0.1% or more, preferably 0.5% or more, and more preferably 1.0% or more, and is 10% or less, preferably 9.5% or less, and more preferably 9% or less. Additionally, surfactant may be added such that the mass ratio between the sulfonamide derivative represented by formula (1), its pharmaceutically acceptable salt, or its active metabolite, and the surfactant becomes in the range of 1:1 to 1:10, and preferably 1:1 to 1:8.
[0070] "Assistant surfactant" refers to the group of solubilizers that exhibit hydrophilicity. Generally, the higher the HLB value, the higher the hydrophilicity. Therefore, in the self-emulsifying compositions of this disclosure, solubilizers with relatively large HLB values can be appropriately selected as assistant surfactants. For example, in this disclosure, solubilizers with HLB greater than 7 can be selected as "assistant surfactants". Specifically, the assistant surfactant is an ester of fatty acid with polyglycerol (HLB>7), an ester of fatty acid with ethylene glycol, an ester of fatty acid with polyethylene glycol, an ester of fatty acid with polyethylene glycol glycerol, a fatty alcohol derivative, or a tocopherol derivative, and more specifically, it is polyoxyethylene 40 castor oil, polyoxyethylene 35 castor oil, PEG-25 trioleate, PEG-60 corn glyceride, PEG-60 almond oil, PEG-40 palm kernel oil, PEG-50 castor oil, PEG-50 hydrogenated castor oil, PEG-60 hydrogenated castor oil, PEG-8 caprylic / capric glyceride, lauric acid glyceride, etc. Acyl polyoxyethylene-32 glycerol ester, linoleyl polyoxyethylene-6 glycerol ester, oleyl polyoxyethylene-6 glycerol ester, stearoyl polyoxyethylene-32 glycerol ester, PEG-6 caprylic / capric glycerol ester, polyglycerol-10 monooleate, polyglycerol-10 laurate, polyglycerol-15 hydroxystearate, or α-tocopherol succinate PEG (e.g., α-tocopherol PEG-400 succinate, α-tocopherol PEG-1000 succinate, dl-α-tocopherol PEG-1000 succinate, or d-α-tocopherol PEG-1000 succinate). Additionally, these auxiliary surfactants may be suitably synthesized by known methods or are commercially available. Non-limiting examples of commercial products include those with names such as Kolliphor, Cremophor, Labrafil, Labrasol, Gellucire, and TPGS in part of their product names. One of these auxiliary surfactants may be used alone, or two or more of these auxiliary surfactants may be combined.
[0071] Among the auxiliary surfactants listed above, the esters of fatty acids with polyethylene glycol glycerol include polyoxyethylene 40 castor oil, polyoxyethylene 35 castor oil, PEG-25 trioleate, PEG-60 corn glyceride, PEG-60 almond oil, PEG-8 caprylic / capric glyceride, lauroyl polyoxyethylene-32 glyceride, linoleyl polyoxyethylene-6 glyceride, oleoyl polyoxyethylene-6 glyceride, stearoyl polyoxyethylene-32 glyceride, and PEG-6 caprylic / capric glyceride. The fatty acid-polyglycerol esters include polyglycerol-10 monooleate, polyglycerol-10 laurate, and polyglycerol-15 hydroxystearate; the fatty acid-polyethylene glycol esters include PEG-50 hydrogenated castor oil and PEG-60 hydrogenated castor oil; and the tocopherol derivatives include α-tocopherol PEG-400 succinate, α-tocopherol PEG-1000 succinate, dl-α-tocopherol PEG-1000 succinate, and d-α-tocopherol PEG-1000 succinate. As the fatty acid-polyglycerol ester, the average molar number of polyethylene glycol added is preferably 20 or greater, and more preferably 32 or greater. The average added molar number of PEG fatty acids of 32 or greater includes PEG glycerol esters such as polyoxyethylene 40 castor oil, polyoxyethylene 35 castor oil, PEG-60 corn glycerol ester, PEG-60 almond oil, lauroyl polyoxyethylene 32 glycerol ester, and stearoyl polyoxyethylene 32 glycerol ester.
[0072] When the total mass of the self-emulsifying composition of this disclosure is considered as 100%, the content of the auxiliary surfactant is preferably 5% by mass or more, more preferably 10% by mass or more, and preferably 85% by mass or less, and more preferably 80% by mass or less. Furthermore, when the content of the sulfonamide derivative represented by formula (1), its pharmaceutically acceptable salt, or its active metabolite is considered as 1 with respect to the sulfonamide derivative represented by formula (1), the content of the auxiliary surfactant is 0.1% or more, preferably 0.5% or more, and more preferably 1.0% or more, and is 10% or less, preferably 9.5% or less, and more preferably 9% or less. Additionally, an auxiliary surfactant may be added such that the mass ratio between the sulfonamide derivative represented by formula (1), its pharmaceutically acceptable salt, or its active metabolite, and the auxiliary surfactant becomes in the range of 1:1 to 1:10, and preferably 1:1 to 1:8.
[0073] The surfactant and co-surfactant can be blended in any desired ratio, as long as an emulsion is formed and exhibits self-emulsifying properties. For example, the ratio of surfactant to co-surfactant can be 1:1 or greater, 1:2 or greater, or 1:3 or greater. For example, the ratio of surfactant to co-surfactant can be 1:10 or less, 1:9 or less, or 1:8 or less. Although not limited to these, the ratio of surfactant to co-surfactant is, for example, 1:1 or greater and 1:10 or less, preferably 1:2 or greater and 1:9 or less, and more preferably 1:3 or greater and 1:8 or less.
[0074] Furthermore, the total content of the surfactant and co-surfactant can be blended in a desired ratio, as long as an emulsion is formed and self-emulsifying properties are exhibited. For example, when the total mass of the self-emulsifying composition is considered 100%, the total content of the surfactant and co-surfactant can be 10% by mass or more, 20% by mass or more, 30% by mass or more, 40% by mass or more, or 50% by mass or more. For example, when the total mass of the self-emulsifying composition is considered 100%, the total content of the surfactant and co-surfactant can be 90% by mass or less. Although not limited thereto, when the total mass of the self-emulsifying composition is considered 100%, the total content of the surfactant and co-surfactant can be 10% by mass or more and 90% by mass or less. The total content of the surfactant and co-surfactant is preferably 20% by mass or more and 90% by mass or less, more preferably 30% by mass or more and 90% by mass or less, further preferably 40% by mass or more and 90% by mass or less, even more preferably 50% by mass or more and 90% by mass or less, and particularly preferably 60% by mass or more and 90% by mass or less.
[0075] The self-emulsifying compositions disclosed herein may also contain a co-solvent. Co-solvents include acetic acid, sorbitol, mannitol, glycerol, triacetyl, triethyl citrate, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, propylene carbonate, ethanol, propylene glycol, etc. These co-solvents may be suitably synthesized by known methods or may be commercially available. One of these co-solvents may be used alone, or two or more of these co-solvents may be combined.
[0076] In the self-emulsifying compositions of this disclosure, the co-solvents can be blended in a desired ratio, provided that the self-emulsifying composition forms an emulsion and exhibits self-emulsifying properties. From the perspective of the commercial production of self-emulsifying drug delivery systems comprising the self-emulsifying compositions of this disclosure and their use in clinical settings, it is desirable that the ratio of the co-solvents be as small as possible. For example, although not limited thereto, when the total mass of the self-emulsifying composition is considered as 100%, the content of the co-solvents may be 1% by mass or more and 15% by mass or less. The co-solvents are preferably 1% by mass or more and 10% by mass or less, more preferably 1% by mass or more and 8% by mass or less, further preferably 1% by mass or more and 5% by mass or less, and particularly preferably 2% by mass.
[0077] In the self-emulsifying compositions disclosed herein, there are no particular limitations on the preferred combination of surfactant, co-surfactant, and co-solvent, as long as the sulfonamide derivative represented by formula (1), its pharmaceutically acceptable salt, or its active metabolite is soluble and exhibits self-emulsifying properties. However, for example, a combination of fatty acid esters with propylene glycol as surfactant, fatty acid esters with polyethylene glycol glycerol or tocopherol derivatives as co-surfactants as co-surfactants, and ethanol as co-solvent is preferred. A combination of propylene glycol monolaurate or propylene glycol monooctanoate as surfactant, polyoxyethylene 40 castor oil, polyoxyethylene 35 castor oil, or α-tocopherol PEG-1000 succinate as co-surfactants as co-surfactants, and ethanol as co-solvent is particularly preferred.
[0078] In the self-emulsifying compositions disclosed herein, there are no particular limitations on the preferred blending ratio of the surfactant, co-surfactant, and co-solvent, as long as the sulfonamide derivative represented by formula (1), its pharmaceutically acceptable salt, or its active metabolite is soluble and exhibits self-emulsifying properties. However, for example, the blending ratio of surfactant:co-surfactant:co-solvent is preferably any one of 45:45:10, 40:50:10, 30:60:10, 22.5:67.5:10, 10:80:10, 11:84:5, or 11:87:2, more preferably any one of 10:80:10, 11:84:5, or 11:87:2, and particularly preferably 11:87:2.
[0079] The self-emulsifying compositions disclosed herein may also contain additives. There are no particular limitations on the additives, provided they are pharmaceutically acceptable and the self-emulsifying composition exhibits self-emulsifying properties. However, additives include, for example, excipients, lubricants, binders, pH adjusters, flavoring agents, thickeners, buffers, colorants, diluents, preservatives, and / or sweeteners. As these additives, one known additive may be used alone, or two or more of these additives may be combined. The blending amounts of these additives may be suitably at any desired ratio, provided the self-emulsifying composition exhibits self-emulsifying ability.
[0080] The self-emulsifying compositions disclosed herein can be suitably formulated pharmaceutically using known methods and used as self-emulsifying drug delivery systems for the treatment or prevention of the diseases described below. Preferably, various drug formulation techniques can be used as a step in drug formulation, provided that the self-emulsifying composition is usable as a SEDDS, SMEDDS, and / or SNEDDS and exhibits self-emulsifying properties. More preferably, drug formulation techniques capable of preparing formulations suitable for oral administration can be selected. Here, "formulations suitable for oral administration" refers to any form of solution, water-based or oil-based suspension, syrup, elixir, emulsion, tablet, pill, ball, granule, fine granule, powder, capsule containing granules, fine granules, or powder, capsule containing solution or suspension, sustained-release system, etc. More preferably, the formulation suitable for oral administration is a capsule, and can be a capsule containing fine granules or powder or a capsule containing solution or suspension.
[0081] The capsules can be hard or soft, but soft capsules are preferred. The composition of the capsule membrane of a soft capsule is not necessarily limited, and its main components include, for example, gelatin, carrageenan, pectin, pullulan, sodium alginate, starch, hydroxypropyl methylcellulose, hydroxypropyl cellulose, and various other known components, but gelatin is preferred. There are no particular limitations on the gelatin, as long as it is commercially available.
[0082] Because the self-emulsifying compositions of this disclosure contain a sulfonamide derivative represented by formula (1), a pharmaceutically acceptable salt thereof, or an active metabolite thereof, the self-emulsifying compositions of this disclosure can be used as therapeutic or preventative agents with α4 integrin inhibitory activity. Here, "therapeutic" means improving clinical symptoms related to a disease or condition, i.e., complete cure, reduction of the degree or frequency of clinical symptoms, or entry into or maintenance of a remission state, and includes operations performed on a living organism of a treated subject for these states, etc., and "preventative" means reducing the risk of developing a disease or condition, and includes operations performed on a living organism not infected with the disease or not exhibiting clinical symptoms to prevent the development of the disease, etc.
[0083] Diseases that can be effectively treated or prevented by using the self-emulsifying compositions of this disclosure or therapeutic or preventive agents containing self-emulsifying compositions include inflammatory diseases in which the pathology involves α4 integrin-dependent adhesion processes. Specifically, such diseases are inflammatory diseases in which α4 integrin is involved in the adhesion process between vascular endothelial cells and inflammatory-associated cells, and more specifically, are diseases that can be treated or prevented by inhibiting α4 integrin to prevent inflammatory-associated cells from infiltrating tissues from the vascular endothelium by a sulfonamide derivative of formula (1), a pharmaceutically acceptable salt thereof, or an active metabolite thereof. Not limited to these, such diseases include, for example, rheumatoid arthritis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus, multiple sclerosis, Sjögren's syndrome, asthma, psoriasis, allergies, diabetes, cardiovascular disease, arteriosclerosis, restenosis, tumor growth, tumor metastasis, transplant rejection, and / or human immunodeficiency virus infection, etc.
[0084] When administered orally in a therapeutically effective amount or an amount sufficient for treatment, the self-emulsifying drug delivery system or therapeutic agent of this disclosure exhibits a useful therapeutic effect on the above-mentioned diseases. Here, "therapeutically effective amount" and "amount sufficient for treatment" have the same meaning and refer to an amount that is effective or sufficient to exert the drug's efficacy when administered to a living organism to treat a disease, and can be determined in various ways based on the sex, age, body type, disease type, disease severity, lifestyle, etc. of the living organism.
[0085] The self-emulsifying compositions, self-emulsifying drug delivery systems, therapeutic agents, and / or preventative agents disclosed herein have the property of being emulsified when orally administered to a living organism and subsequently mixed with gastrointestinal fluids. Furthermore, emulsification allows the sulfonamide derivative represented by formula (1) or a pharmaceutically acceptable salt thereof to dissolve from the emulsion formed by the self-emulsifying drug delivery system. Here, "gastrointestinal fluids" refers to liquid components secreted from the mouth, esophagus, stomach, small intestine, large intestine, etc., of a living organism, or liquid components present in the gastrointestinal tract, and specifically refers to saliva, gastric acid, bile, pancreatic juice, intestinal juice, etc. Because these gastrointestinal fluids possess a variety of liquid properties ranging from acidic to neutral conditions, self-emulsifying drug delivery systems preferably have the property of allowing compounds to dissolve from the formed emulsion as the system passes through the gastrointestinal tract after oral administration. More preferably, they have the property of allowing compounds to dissolve from the formed emulsion within a pH range exhibited by the gastrointestinal fluid, from acidic to neutral conditions. Even more preferably, they have the property of allowing compounds to dissolve from the formed emulsion within a wide pH range, from acidic to neutral conditions. Particularly preferably, they have the property of allowing compounds to dissolve from the formed emulsion within a wide pH range, from acidic to neutral conditions, and allowing compounds to dissolve more readily under acidic conditions than under neutral conditions. Here, acidic conditions are typically conditions involving mixing with gastric acid in the stomach and generally refer to a pH of around 2.0 to 3.0. Neutral conditions are typically conditions involving mixing with bile, pancreatic juice, or intestinal fluid in the small or large intestine and generally refer to a pH of around 6.0 to 7.5.
[0086] In one aspect of this disclosure, for example, the self-emulsifying drug delivery system has the property of allowing compounds to dissolve more under acidic conditions than when a sulfonamide derivative represented by formula (1), its pharmaceutically acceptable salt, or its active metabolite is dissolved in an aqueous solution of methylcellulose. Additionally, in another aspect of this disclosure, for example, the self-emulsifying drug delivery system has the property of allowing compounds to dissolve more under acidic conditions than when a sulfonamide derivative represented by formula (1), its pharmaceutically acceptable salt, or its active metabolite is dissolved in a polyethylene glycol solution.
[0087] The absorption of self-emulsifying compositions, self-emulsifying drug delivery systems, therapeutic agents, and / or prophylactic agents in the gastrointestinal tract can be directly or indirectly assessed experimentally. Specifically, absorption can be assessed by exposing the self-emulsifying composition to conditions ranging from acidic to neutral, and can be evaluated in vitro or in vivo. Not limited thereto, as an in vitro experiment, for example, the test tube method described below can be used. Furthermore, not limited thereto, as an in vivo experiment, for example, a PO / PK experiment can be used, in which blood is collected over time after oral administration of the self-emulsifying composition to rodents or non-rodents, and the blood concentrations of the active pharmaceutical ingredient and / or its active metabolites are subsequently analyzed. Non-rodents are typically dogs, monkeys, or humans. By plotting the blood concentrations thus obtained on the vertical axis and the elapsed time period on the horizontal axis, a curve indicating the change in blood concentration over time can be shown, and the area under the curve (AUC) of this curve can also be used to assess absorption.
[0088] In one aspect of this disclosure, for example, the self-emulsifying drug delivery system exhibits a higher AUC than when a sulfonamide derivative represented by formula (1), its pharmaceutically acceptable salt, or its active metabolite is dissolved in an aqueous solution of methylcellulose. Additionally, in another aspect of this disclosure, it is preferred that the self-emulsifying drug delivery system exhibits a higher AUC than when a sulfonamide derivative represented by formula (1), its pharmaceutically acceptable salt, or its active metabolite is dissolved in a polyethylene glycol solution.
[0089] From the perspective of ease of evaluation, for example, the test tube method is preferred as an in vitro experiment. The test tube method is as follows: A solution of a self-emulsifying composition in which a certain amount of the compound is dissolved is prepared and first added to a test liquid simulating the acidic conditions of the stomach. After a desired time period, a small sample of the test liquid is taken. Subsequently, the test liquid is added under neutral conditions simulating the small intestine, and the same operation is repeated. Then, the test liquid is further added under neutral conditions simulating the large intestine, and the same operation is repeated. The amount of the compound in each of the test liquids obtained as described above is then quantified using known analytical methods such as high-performance liquid chromatography, gas chromatography, supercritical fluid chromatography, or mass spectrometry, thereby indirectly assessing absorbability based on the dissolution rate under each condition.
[0090] Here, the "dissolution rate" in this specification is a numerical value obtained by expressing the amount of compound dissolved from the formed emulsion into the test liquid as a percentage, when the amount of compound dissolved in the solution of the desired self-emulsifying composition is considered 100%. Furthermore, by plotting the concentration of the compound in the test liquid under each experimental condition on the vertical axis and the elapsed time period on the horizontal axis, a curve indicating the change in the concentration of the compound in the test liquid over time can be shown. The AUC of this curve can also be used for the assessment of absorbability.
[0091] Example The invention disclosed herein will be described in detail below using examples.
[0092] (Production Example 1) Preparation of self-emulsifying compositions 1 to 84 Weigh and mix each surfactant, co-surfactant, and co-solvent, and add the active pharmaceutical ingredient (compound (1)) to the mixture thus obtained, followed by treatment at 50°C using an ultrasonic homogenizer to prepare the self-emulsifying compositions 1 to 84 shown in Tables 1 to 7. The values in Tables 1 to 7 represent mass%.
[0093] Table 1
[0094] Table 2
[0095] Table 3
[0096] Table 4
[0097] Table 5
[0098] Table 6
[0099] Table 7
[0100] The surfactants listed in Tables 1 to 7 above are as follows.
[0101] • Capryol 90: Propylene glycol monooctanoate (Type II) • Capmul MCM C8: Caprylic / Caprylic Acid Glyceryl Monoester • Plurol Oleique CC497: Polyglyceryl-3-dioleate • Lauroglycol 90: Propylene glycol monolaurate (Type II) • Lauroglycol FCC: Propylene glycol monolaurate (Type I) • Capryol PGMC: Propylene glycol monocaprylate (Type I) The auxiliary surfactants listed in Tables 1 to 7 above are as follows.
[0102] • Labrasol ALF: PEG-8 Caprylic / Capric Glyceryl Acetate • Kolliphor EL: Polyoxyethylene 35 Castor Oil • Kolliphor RH40: Polyoxyethylene 40 castor oil • Kolliphor HS15: Polyglycerol-15-hydroxystearate • Gelucire 44 / 14: Lauroyl polyoxyethylene-32-glycerol ester • Gelucire 48 / 16: Stearoyl polyoxyethylene-32-glyceryl ester • Gelucire 50 / 13: Stearoyl polyoxyethylene-32-glyceryl ester •TPGS: d-α-tocopherol PEG-1000 succinate • Tween 80: Polysorbate 80 • BRIJ S10: Polyethylene glycol octadecyl ether • LABRAFIL M2125CS: Linoleoyl polyoxyethylene-6-glycerol ester • LABRAFIL M1944CS: Oleoyl polyoxyethylene-6-glycerol ester • Sucrose myristate In the self-emulsifying compositions of Production Example 1, the correspondences of self-emulsifying compositions having the same component composition except for concentration and the same component ratio except for the active pharmaceutical ingredient are shown in Table 8. Self-emulsifying compositions 85 to 87 were prepared according to Production Example 1. Self-emulsifying composition 85 contains 1.5% by mass of the active pharmaceutical ingredient, 44.325% by mass of Capryol 90, 44.325% by mass of Labrasol ALF, and 9.85% by mass of ethanol. Self-emulsifying composition 86 contains 1.5% by mass of the active pharmaceutical ingredient, 44.325% by mass of Capryol 90, 44.325% by mass of Kolliphor EL, and 9.85% by mass of ethanol. Self-emulsifying composition 87 contains 1.5% by mass of the active pharmaceutical ingredient, 9.85% by mass of Capryol 90, 78.8% by mass of Kolliphor EL, and 9.85% by mass of ethanol.
[0103] Table 8
[0104] (Production Example 2) Preparation of the Comparative Example Composition Weigh 1 g of polyethylene glycol 400 and add the active pharmaceutical ingredient to it at a specified concentration. Then, treat the solution at 50°C using an ultrasonic homogenizer to prepare PEG solutions with active pharmaceutical ingredient concentrations of 15 mg / g (PEG solution 1), 50 mg / g (PEG solution 2), and 100 mg / g (PEG solution 3). Separately, add the active pharmaceutical ingredient to 1 g of a 0.5% methylcellulose aqueous solution prepared by adding 125 mg of methylcellulose 400 and dissolving it in 25 mL of purified water at a specified concentration. Then, treat the solution at 50°C using an ultrasonic homogenizer to prepare MC solutions with active pharmaceutical ingredient concentrations of 15 mg / g (MC solution 1), 50 mg / g (MC solution 2), and 100 mg / g (MC solution 3).
[0105] (Evaluation 1-1) Dissolution test: test tube method Add 1.0 mL of 0.5% methylcellulose aqueous solution to 1.5 mL of HCl / saline aqueous solution adjusted to pH 2.0, and then shake at 37°C and 90 rpm to obtain a test liquid. Add 100 mg of the self-emulsifying compositions 1 to 84 prepared in Production Example 1, PEG solution 2 or 3 prepared in Production Example 2, or MC solution 2 as a test sample to this test liquid, mix by inversion, and then shake at 37°C and 90 rpm. Then, 15 minutes after adding the test sample, take a 500 μL sample of the test liquid and quickly filter the sampled solution using a filter vial integrated with a filter (Mini-UniPrep, 45 μm pore size) and centrifuge to obtain a supernatant. Add 100 μL of acetonitrile and 600 μL of water / acetonitrile mixture (1:1) to 100 μL of the supernatant to obtain a gastric segment sample (pH 2.4). After sampling the gastric segment, 7.5 mL of FaSSIF preheated to 37°C was added, followed by shaking at 37°C and 90 rpm. Then, at 30 min, 30 min, 60 min, 90 min, and 120 min after adding FaSSIF, 500 μL of the test liquid was sampled and rapidly filtered using a filter vial integrated with a filter (Mini-UniPrep, 45 μm pore size), and centrifuged to obtain the supernatant. 200 μL of acetonitrile was added to 200 μL of the supernatant to obtain the small intestine segment sample (pH 6.4). Each sample was analyzed by high-performance liquid chromatography (HPLC) to measure the drug dissolution rate in the gastric or small intestine segment. The HPLC analytical conditions are as follows.
[0106] <hplc> Detector: Ultraviolet absorber (measurement wavelength: 264 nm) Column: A stainless steel tube with an inner diameter of 3.0 mm and a length of 150 mm, filled with octadecylsilane silica gel for liquid chromatography with a particle size of 2.7 μm.
[0107] Column temperature: constant at around 30℃ Flow rate: 0.5 mL / min Area measurement range: 6 minutes after sample injection Mobile phase: 25 mM ammonium acetate solution (pH 5.0) / acetonitrile mixture (13:12) The dissolution rates at pH 2.4 or pH 6.4 for the corresponding self-emulsifying compositions 1 to 84 are shown in Tables 9 to 15. Additionally, for self-emulsifying compositions 1 to 38, the AUC values (test tube AUC) of the curves obtained by plotting time (0 to 2.25 hours) on the horizontal axis and the dissolution rate on the vertical axis are... 0-2.25 ) and its logarithm (test tube method Log AUC) 0-2.25 The values are shown in Tables 9 to 12. Furthermore, the dissolution rates at pH 2.4 or pH 6.4 for the corresponding PEG solution 2, PEG solution 3, and MC solution 2, and the AUC values (test tube AUC) of the curves obtained by plotting time (0 to 2.25 hours) on the horizontal axis and dissolution rate on the vertical axis, are also shown. 0-2.25 ) and its logarithm (test tube method Log AUC) 0-2.25 (See Table 16.)
[0108] Table 9
[0109] Table 10
[0110] Table 11
[0111] Table 12
[0112] Table 13
[0113] Table 14
[0114] Table 15
[0115] Table 16
[0116] Dissolution test: test tube method The above dissolution test was performed to measure the dissolution rate and to calculate the value of AUC (test tube method AUC 0-2.25 ) and the logarithmic value thereof (test tube method Log AUC 0-2.25 ) for self-emulsifying compositions 85 to 87 and a self-emulsifying composition (hereinafter referred to as self-emulsifying composition 88) prepared in the same manner as self-emulsifying composition 30 except that 10 mass% of active pharmaceutical ingredient, 11 mass% of Capryol 90, 77.2 mass% of Kolliphor EL, and 1.8 mass% of ethanol were contained, and MC solution 1 and MC solution 3 prepared in Production Example 2. The results are shown in Table 17.
[0117] Table 17
[0118] Plasma concentration evaluation 1 by PO / PK experiment using rats (evaluation 2-1) Each of self-emulsifying compositions 85 to 87 was orally administered to each group of 3 male rats (Crl:CD (SD)) under fasting conditions, and the transition of the plasma concentration of the active metabolite of the active pharmaceutical ingredient was evaluated. Note that the fasting conditions were such that fasting was started about 15 hours or more before administration. An amount equivalent to 3 mg / kg of the active pharmaceutical ingredient of the self-emulsifying composition was administered to each animal. Blood was collected from the subclavian vein at 0.25 hours, 0.5 hours, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, and 24 hours after administration, and plasma was sampled by centrifugation operation. After deproteinization of the plasma by using acetonitrile, the concentration of the active metabolite in the plasma was measured by using LC-MS / MS (API4000, manufactured by AB SCIEX). In addition, as a control group, test animals to which PEG solution 1 or MC solution 1 prepared in Production Example 2 was administered. The Tmax, Cmax, and AUC of the concentration of the active metabolite in the plasma thus obtained are shown in Table 18.
[0119] Table 18
[0120] Plasma concentration evaluation 2 by PO / PK experiment using rats (evaluation 2-2) The changes in the total concentration of the active pharmaceutical ingredient and its active metabolites in plasma were assessed in the same manner as in assessment 2-1, except that each animal was administered an amount of self-emulsifying composition 28 or 29 equivalent to 100 mg / kg or 300 mg / kg of the active pharmaceutical ingredient. Additionally, as a control group, test animals were administered PEG solution 3 prepared in Production Example 2. The Cmax and AUC of the concentrations of the active pharmaceutical ingredient and active metabolites in plasma obtained at a dose of 100 mg / kg are shown in Table 19. Furthermore, the Cmax and AUC of the concentrations of the active pharmaceutical ingredient and active metabolites in plasma obtained at a dose of 300 mg / kg are shown in Table 20.
[0121] Table 19
[0122] Table 20
[0123] (Assessment 3) Assessment of plasma concentrations in dogs using PO / PK assay Each of the self-emulsifying compositions 28 and 88 prepared in Production Example 1 was orally administered to three male beagle dogs (10 to 15 months of age) under fasting conditions, and the changes in plasma concentrations of the active pharmaceutical ingredient and active metabolites were assessed. It should be noted that the fasting conditions required fasting to begin 16 hours or longer prior to administration. Each animal was administered a gelatin capsule filled with the self-emulsifying composition, equivalent to 100 mg / kg of the active pharmaceutical ingredient. Blood was collected from the cephalic vein at 0.25, 0.5, 1, 2, 4, 6, 8, 10, and 24 hours after administration, and plasma samples were taken and processed. The total concentrations of the active pharmaceutical ingredient and active metabolites in plasma were measured using LC-MS / MS (API4000, manufactured by AB SCIEX). Additionally, as a control group, test animals administered PEG solution 3 prepared in Production Example 2 were used. The Tmax, Cmax, and AUC of the concentrations of the active drug components and active metabolites in plasma thus obtained are shown in Table 21.
[0124] Table 21
[0125] (Evaluation 4) Correlation between the test tube method and the PO / PK experiment The logarithm of the AUC obtained in Evaluation 1 for the test tube method (test tube method Log AUC) will be used. 0-2.25 The results are plotted on the horizontal axis and the logarithm of the AUC of the plasma concentration obtained in Assessment 2 (rat PO / PK Log AUC) is plotted on the vertical axis. Figure 1 As shown in the figure. Additionally, the logarithm of the AUC obtained in Evaluation 1 (Test Tube Method Log AUC) is used. 0-2.25 The results are plotted on the horizontal axis and the dissolution rate (%) at pH 2.4 or pH 6.4 is plotted on the vertical axis. Figure 2 or Figure 3 As shown in the image. Additionally... Figures 1 to 3 The corresponding correlation coefficients are shown in Table 22. AUC of the test tube method. 0-2.25 The AUC of rat PO / PK showed a strong positive correlation, and the AUC of the test tube method was also positively correlated. 0-2.25 The dissolution rate showed a positive correlation with the pH at 2.4 and 6.4. This can be determined by the AUC of the test tube method. 0-2.25 The results or dissolution rates at pH 2.4 or pH 6.4 are used to infer the pharmacokinetics (AUC) in vivo.
[0126] Table 22
[0127] The self-emulsifying composition disclosed herein can improve the absorption of sulfonamide derivatives represented by formula (1) after oral administration.< / hplc>
Claims
1. A self-emulsifying composition comprising: a sulfonamide derivative represented by formula (1), a pharmaceutically acceptable salt thereof, or an active metabolite thereof; and at least two solubilizers, 。 2. The self-emulsifying composition according to claim 1, wherein the at least two solubilizers comprise at least one surfactant and at least one auxiliary surfactant.
3. The self-emulsifying composition according to claim 1, wherein the solubilizer comprises at least two selected from cyclodextrin or its derivatives, bile acids or their derivatives, fatty alcohols, fatty acids or their derivatives, and tocopherol derivatives.
4. The self-emulsifying composition according to claim 2, wherein the surfactant comprises at least one selected from the group consisting of polyglycerol-2 dioleate, polyglycerol-3 dioleate, polyglycerol-10 trioleate, propylene glycol monolaurate, propylene glycol monocaprylate, glyceryl monocaprylate, glyceryl monolaurate, glyceryl dilaurate, and glyceryl monolinoleate.
5. The self-emulsifying composition according to claim 2, wherein the auxiliary surfactant comprises selected from polyoxyethylene 40 castor oil, polyoxyethylene 35 castor oil, PEG-25 trioleate, PEG-60 corn glyceride, PEG-60 almond oil, PEG-40 palm kernel oil, PEG-50 castor oil, PEG-50 hydrogenated castor oil, PEG-60 hydrogenated castor oil, PEG-8 caprylic / capric glyceride, lauroyl polyoxyethylene-32 glyceride, linoleyl polyoxyethylene- At least one of the group consisting of 6-glyceryl ester, oleoyl polyoxyethylene-6-glyceryl ester, stearoyl polyoxyethylene-32-glyceryl ester, PEG-6 caprylic / capric glyceryl ester, polyglycerol-10 monooleate, polyglycerol-10 laurate, polyglycerol-15 hydroxystearate, α-tocopherol PEG-400 succinate, α-tocopherol PEG-1000 succinate, dl-α-tocopherol PEG-1000 succinate, and d-α-tocopherol PEG-1000 succinate.
6. The self-emulsifying composition according to any one of claims 2, 4, and 5, wherein... The content of the surfactant is 0.1 times or more by mass% relative to the sulfonamide derivative or its pharmaceutically acceptable salt represented by formula (1), and The content of the auxiliary surfactant is 10 times or less relative to the sulfonamide derivative or its pharmaceutically acceptable salt represented by formula (1).
7. The self-emulsifying composition according to any one of claims 2, 4 and 5, wherein the ratio of the surfactant to the auxiliary surfactant is from 1:1 to 8:
1.
8. The self-emulsifying composition according to claim 2 or 4, wherein the surfactant comprises propylene glycol monooctanoate.
9. The self-emulsifying composition according to claim 2 or 5, wherein the auxiliary surfactant comprises polyoxyethylene 40 castor oil, polyoxyethylene 35 castor oil, or polyoxyethylene castor oil.
10. The self-emulsifying composition according to claim 1 or 2, further comprising a co-solvent.
11. A self-emulsifying drug delivery system in a formulation suitable for oral administration, comprising the self-emulsifying composition according to claim 1 or 2.
12. The self-emulsifying drug delivery system of claim 11, wherein the formulation is a capsule.
Citation Information
Patent Citations
Self-emulsion composition of ω3 fatty acid
JP2021107433A
Self-emulsifying formulation for improving membrane penetration of compound
JP2021169476A
Sulfonamide derivative and pharmaceutical composition containing same
WO2017135472A1
